74907L409

Confident Investing Starts Here:

• Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
• Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

Quoin Pharmaceuticals ( (QNRX) ) has issued an update.

On May 29, 2025, Quoin Pharmaceuticals Ltd.’s Compensation Committee approved 2024 annual cash bonuses for Dr. Michael Myers and Ms. Denise Carter, amounting to $331,238 and $264,640 respectively. These bonuses align with the CEO and COO Compensation Programs approved at the company’s annual meeting on December 5, 2024, reflecting the company’s commitment to rewarding its executive leadership.

The most recent analyst rating on (QNRX) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.

Spark’s Take on QNRX Stock

According to Spark, TipRanks’ AI Analyst, QNRX is a Underperform.

Quoin Pharmaceuticals is in a challenging financial position with no revenue generation and high reliance on external financing. The technical analysis indicates a bearish trend, though some technical indicators suggest the stock may be oversold. Valuation metrics reflect the company’s lack of profitability. The combination of these factors results in a low stock score, highlighting significant risks to investors.

To see Spark’s full report on QNRX stock, click here.

More about Quoin Pharmaceuticals

Average Trading Volume: 287,284

Technical Sentiment Signal: Sell

Current Market Cap: $5.14M

See more data about QNRX stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue